Clinical Trial Protocol Registry
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients With Acute Heart Failure.
- Protocol number:
- Company division:
- Official Scientific Title:
- NT-proBNP in the optimization of treatment after recent acute heart failure (BOT-Acute HF) trial.
- Brief summary:
- This study will assess whether measurement of NT-proBNP levels before discharge from hospital after acute heart failure improves the prognosis of patients, with respect to major cardiovascular events (cardiovascular hospitalizations and cardiac deaths).
- Study type:
- Interventional; Randomized; Open Label; Parallel study
- Heart Failure
- Intervention type:
- Diagnostic Test
- Intervention name:
- Inclusion criteria:
- adult patients, >=18 years of age;
- hospital admission for acute heart failure, class III or IV;
- requirement for intravenous therapy.
- Exclusion criteria:
- clinical or laboratory evidence of an acute coronary syndrome;
- major arrhythmias as the main cause of symptoms;
- PTCA or CABG planned in next 3 months;
- non-cardiac concomitant diseases which may have an important influence on outcome as primary factor.
- Males or Females
- Age limits:
- Min: 18Years Max: N/A (No limit)
- Accepts healthy volunteers:
- Anticipated start date:
- July, 2006
- Trial registration date:
- Date last updated:
For more information on a specific Roche trials in your country location, please contact your local Roche affiliate nearest you.
- Go on the URL link- http://www.roche.com and click on the Roche Worldwide tab on the top of the page to locate the country nearest you for contact information.
Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the global studies, please have your healthcare provider contact us and they will be provided with the relevant clinical trial information.
For US or global trials with US sites only, please contact the Trial Information Support Line (TISL)
- 1-888-662-6728 Monday to Friday (6am to 3pm PST)